ProMIS Neurosciences Stock Surges on Positive Alzheimer's Drug Safety Data

ProMIS Neurosciences (PMN) stock surged 16.1% in pre-market trading after the company released positive interim safety data from a trial of its lead Alzheimer's disease candidate, PMN310. The results notably showed zero cases of brain swelling, a significant and feared side effect associated with other treatments in the class.

Key Trial Results

The clinical-stage biopharmaceutical company unveiled the six-month blinded safety and biomarker results from its PRECISE-AD Phase 1b trial during a webinar. The data from 136 patients was highly encouraging, particularly regarding safety.

Key findings include:

• Zero cases of amyloid-related imaging abnormalities-edema (ARIA-E), a form of brain swelling that has been a major challenge for competing Alzheimer's immunotherapies.
• The total incidence of ARIA was just 4.4%, consisting entirely of mild, asymptomatic microhemorrhages.
• No treatment-related serious adverse events or drug-related discontinuations were reported.

Ad

The positive safety profile was observed across a genetically diverse patient group, including high-risk individuals. According to the company, 61% of participants were APOE4 carriers, with 11% being homozygotes, a subgroup more susceptible to ARIA-E.

Market Reaction and Analyst Outlook

The news triggered a strong positive reaction from investors, sending the stock to $13.61 in pre-open trading from its prior close of $11.72. The move was entirely company-specific, running counter to a mixed broader market where the tech-heavy Nasdaq was trading lower.

Adding to the bullish sentiment, investment bank Chardan initiated coverage on ProMIS the previous day with a Buy rating and a $20.00 price target. This follows recent Buy or Overweight ratings from other firms, including H.C. Wainwright, Roth Capital, and Cantor Fitzgerald, indicating a growing positive consensus among analysts.